

Clinical Policy: Step Therapy

Reference Number: CP.CPA.83

Effective Date: 09.01.18

Last Review Date: 08.21

Line of Business: Commercial*

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

This policy provides a list of drugs that require step therapy.

**This step therapy policy does not apply to drugs that are not on the Commercial formulary. For non-formulary drugs, refer to the formulary exception policy, CP.CPA.190 Formulary Exceptions.*

FDA Approved Indication(s)

Various

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that the following drugs are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Step Therapy:

Drugs listed in the table below may be approved for the length of benefit for members who have had a previous trial of or who have contraindications to required step-through agents, when the request does not exceed the maximum indicated dose and stated quantity limit.

Drug Name	Required Step-Through Agents	Maximum Dose (Quantity Limit)
aliskiren (Tekturna [®]), aliskiren/HCTZ (Tekturna HCT [®])	ARB or ARB combination product (e.g., olmesartan, olmesartan/hctz, irbesartan, losartan, candesartan, telmisartan, valsartan)	Tekturna: 300 mg/day Tekturna HCT: 300/25 mg/day
Aplenzin [®] (bupropion hydrobromide SR)	Two generic antidepressants	348 mg/day (1 tablet/day)
Astagraf XL [®] (tacrolimus SR)	Generic tacrolimus	0.2 mg/kg/day
Bepreve [®] (bepotastine)	Generic ophthalmic olopatadine, and either azelastine or epinastine	2 drops/eye/day (0.34 mL/day)

Drug Name	Required Step-Through Agents	Maximum Dose (Quantity Limit)
calcipotriene-betamethasone ointment (Taclonex [®])	Generic topical steroid and either topical calcitriol or calcipotriene cream	100 g/week (2 g/day)
calcipotriene-betamethasone suspension (Taclonex [®])	Generic clobetasol and fluocinolone	100 g/week (2 g/day)
Cimduo [™] (lamivudine/tenofovir disoproxil fumarate)	If treatment naïve: Truvada [®] (emtricitabine/tenofovir disoproxil fumarate)	Adults and pediatric patients weighing ≥ 35 kg: 200/300 mg PO QD Pediatric patients weighing between 17 to < 35 kg: 17 kg to < 22 kg: 100/150 mg PO QD 22 kg to < 28 kg: 133/200 mg PO QD 28 kg to < 35 kg: 167/250 mg PO QD
desoximetasone spray 0.25% (Topicort [®])	Generic desoximetasone 0.25% ointment and cream	Not applicable
desvenlafaxine succinate ER (Khedeza [®] , Pristiq [®])	Two generic antidepressants	400 mg/day (or 100 mg/day in moderate to severe hepatic impairment) (1 tablet/day)
Envarsus [®] XR (tacrolimus SR)	Generic tacrolimus	Not applicable
ethacrynic acid (Edecrin [®])	Generic bumetanide, furosemide, or torsemide	400 mg/day
Fetzima [®] (levomilnacipran)	Two generic antidepressants	120 mg/day (20 mg: 2 tablets/day; Other strengths: 1 tablet/day)
Forfivo XL [®] (bupropion hydrochloride ER)	Two generic antidepressants	450 mg/day (1 tablet/day)
Lastacraft [®] (alcaftadine ophthalmic solution 0.25%)	Both of the following (a and b): a) Patanol or Pataday b) Azelastine or Epinastine	(1 drop/eye/day) 1 bottle/month
modafinil (Provigil [®])	armodafinil (Nuvigil [®])	200 mg/day for shift work disorder; 400 mg for all other indications
olmesartan/amlodipine (Azor [™]),	Generic or formulary preferred ARB or ARB	Azor: 10/40 mg/day

Drug Name	Required Step-Through Agents	Maximum Dose (Quantity Limit)
olmesartan/amlodipine/HCTZ (Tribenzor [™])	combination product (e.g., olmesartan, olmesartan/hctz, irbesartan, losartan, candesartan, telmisartan, valsartan)	Tribenzor: 40/10/25 mg/day
olopatadine HCl ophthalmic solution 0.7%	Generic ophthalmic olopatadine, and either azelastine or epinastine	1 bottle/month
Oxtellar XR [®] (oxcarbazepine SR 150 mg, 300 mg, 600 mg)	Generic Trileptal	2,400 mg/day
risedronate (Actonel [®])	One of the following generic bisphosphonates: ibandronate, alendronate, or risedronate (Atelvia [®])	150 mg/month (5 mg, 30 mg: 1 tablet/day; 35 mg: 0.15 tablet/day; 150 mg: 0.04 tablet/day)
Trintellix [®] (vortioxetine)	Two generic antidepressants	20 mg/day (1 tablet/day)
Viibryd [™] (vilazodone)	Two generic antidepressants	40 mg/day
zileuton ER (Zyflo [®] CR)	Generic montelukast	2,400 mg/day
Zyflo [®] (zileuton)	Generic montelukast	2,400 mg/day

Agents are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Approval duration: Length of Benefit

II. Continued Therapy

A. Step Therapy (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Documentation supports that member is currently receiving Cimduo for HIV infection and has received this medication for at least 30 days;
2. If request is for a dose increase, new dose does not exceed the FDA-approved maximum recommended dose and quantity limit as stated in the initial approval criteria for the relevant drug.

Approval duration: Length of Benefit

III. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ARB angiotensin receptor blocker

CR: controlled-release

ER: extended-release

FDA: Food and Drug Administration

HCTZ: hydrochlorothiazide

HIV: human immunodeficiency virus

IR: immediate-release

SR: sustained-release

XL: extended-release

Appendix B: Therapeutic Alternatives

Refer to the required step-through drugs above in Section I.

Appendix C: Contraindications/Boxed Warnings

Refer to the package inserts for each of the drugs requiring step therapy.

IV. Dosage and Administration

Refer to the step therapy table in Section I.

V. Product Availability

Drug Name	Availability
Aliskiren (Tekturna)	Tablets: 150, 300 mg
Aliskiren/HCTZ (Tekturna HCT)	Tablets: 150/12.5, 150/25, 300/12.5, 300/25 mg
Bepotastine (Bepreve)	Ophthalmic solution, 1.5%: 5 mL, 10 mL
Bupropion hydrobromide ER (Aplenzin)	Tablets, extended release: 174 mg, 348 mg, 522 mg
Bupropion hydrochloride ER (Forfivo XL)	Tablets, extended release: 450 mg
Calcipotriene-betamethasone (Taclonex)	Topical ointment, 0.005%/0.064%: 60 g, 100 g Topical suspension, 0.005%/0.064%: 60 g, 100 g
Cimduo (lamivudine/tenofovir disoproxil fumarate)	Tablets: 300 mg lamivudine/ 300 mg tenofovir disoproxil fumarate
Desvenlafaxine succinate (Pristiq [®] , Khedezla [®])	Tablets, extended release: 25 mg (Pristiq only), 50 mg, 100 mg
Ethacrynic acid (Edecrin)	Tablets: 25 mg
Levomilnacipran (Fetzima)	Capsules, extended release: 20 mg, 40 mg, 80 mg, 120 mg Capsules, extended release therapy pack: 20 mg/40 mg
Modafinil (Provigil [®])	Tablets: 100 mg, 200 mg
Olmesartan/amlodipine (Azor)	Tablets: 5/20, 10/20, 5/40, 10/40 mg
Olmesartan/amlodipine/HCTZ (Tribenzor)	Tablets: 20/5/12.5, 40/5/12.5, 40/5/25, 40/10/12.5, 40/10/25 mg
Risedronate (Actonel)	Tablets: 5 mg, 30 mg, 35 mg, 150 mg
Tacrolimus SR (Astagraf XL)	Capsules, extended release: 0.5 mg, 1 mg, 5 mg
Tacrolimus SR (Envarsus XR)	Tablets, extended release: 0.75 mg, 1 mg, 4 mg
Vilazodone (Viibryd)	Tablets: 10 mg, 20 mg, 40 mg Tablets, starter pack: 10 mg/20 mg
Vortioxetine (Trintellix)	Tablets: 5 mg, 10 mg, 20 mg
Zileuton (Zyflo)	Tablets: 600 mg
Zileuton SR (Zyflo CR)	Tablets, extended release: 600 mg

VI. References

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2020. Available at: <http://www.clinicalpharmacology-ip.com/>. Accessed February 24, 2021.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
New policy created from step therapy policy CP.CPA.219 Antidepressant Step Therapy and CP.CPA.185 General Step Through Criteria.	05.15.18	08.18
Changes align with previously approved clinical guidance: Added Atripla, Odefsey, and Complera to policy requiring step through Symfi if member is treatment naïve per SDC; added continuation of care language for HIV per SDC.	12.07.18	
Changes align with previously approved clinical guidance: added Symtuza to policy requiring step through Symfi if member is treatment naïve per SDC.	12.19.18	
Changes align with previously approved clinical guidance: added Delstrigo to policy requiring step through Symfi if member is treatment naïve per SDC.	02.01.19	
2Q 2019 annual review: added Provigil to policy requiring step through Nuvigil; references reviewed and updated.	03.05.19	05.19
Azor and Tribenzor added to policy requiring step through generic or formulary preferred ARB or ARB combination product; retire CP.CPA.61; added Tekturna and Takturna HCT to policy requiring step through ARB or ARB combination product; retire CP.CPA.07.	05.06.19	08.19
Seebri Neohaler and Tudorza Pressair added to policy requiring use of preferred Spiriva or Incruse Ellipta per SDC and prior clinical guidance; retire CP.CPA.150. Added disclaimer statement that policy does not apply to NF drugs.	10.07.19	
2Q 2020 annual review: no significant changes.	03.05.20	05.20
Added Cimduo requiring use of Truvada for treatment naïve members per April SDC and prior clinical guidance.	04.27.20	
Removed Tudorza Pressair and Seebri Neohaler per October SDC and prior clinical guidance.	10.07.20	
Removed Atripla per November SDC and prior clinical guidance	11.16.20	
2Q 2021 annual review: added the following: Lastacraft requiring step through Patanol or Pataday and either azelastine or epinastine; olopatadine ophthalmic solution 0.7% requiring step through generic ophthalmic olopatadine, and either azelastine or epinastine; Oxtellar requiring step through Trileptal; added desoximetasone spray requiring step through generic desoximetasone ointment and cream; references reviewed and updated.	02.24.21	05.21
Per June SDC and prior clinical guidance, removed Symtuza, Complera, Delstrigo, and Odefsey from policy.	06.02.21	08.21

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.